TVRD
Tvardi Therapeutics, Inc.
Overview
Tvardi Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $25.1M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 12, 2026).
12 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2023Earnings2024-03-0410 Q&A exchanges
- Q3 FY2023Earnings2023-11-1315 Q&A exchanges
- Q2 FY2023Earnings2023-08-0714 Q&A exchanges
- Q1 FY2023Earnings2023-05-1515 Q&A exchanges
- Q4 FY2022Earnings2023-03-0622 Q&A exchanges
- Q3 FY2022Earnings2022-11-0712 Q&A exchanges
- Q2 FY2022Earnings2022-08-0818 Q&A exchanges
- Q1 FY2022Earnings2022-05-0922 Q&A exchanges
- Q4 FY2021Earnings2022-03-0115 Q&A exchanges
- Q3 FY2021Earnings2021-11-0810 Q&A exchanges
- Q2 FY2021Earnings2021-08-0919 Q&A exchanges
- Q1 FY2021Earnings2021-05-1020 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-12EPS— vs $-0.61—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | — | $-0.61 | — | — | — | — | EODHD |
Source: EODHD. TVRD reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks TVRD's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2023 | $2.05 | $1.88 | +9.1% | +6.1% | +8.4% |
| Q4 FY2023 | $2.28 | $1.89 | +20.6% | +4.0% | +1.5% |
| Q3 FY2023 | $2.12 | $1.88 | +12.9% | -4.5% | -3.0% |
| Q2 FY2023 | $2.07 | $1.82 | +13.7% | -3.4% | -4.9% |
| Q1 FY2022 | $2.19 | $2.02 | +8.6% | +4.8% | +2.4% |
| Q4 FY2022 | $2.23 | $1.95 | +14.3% | -2.7% | -2.6% |
| Q3 FY2022 | $2.53 | $2.10 | +20.3% | -3.3% | -2.1% |
| Q2 FY2022 | $2.32 | $1.97 | +17.8% | +4.8% | +7.5% |
| Q1 FY2021 | $2.11 | $1.86 | +13.7% | +3.4% | +5.7% |
| Q4 FY2021 | $2.46 | $2.03 | +21.2% | -2.5% | -0.9% |
Guidance change history
Sample- Q1 FY2023Raised2023-04-15
- Q4 FY2023Raised2023-13-15
- Q3 FY2023Raised2023-10-15
- Q2 FY2023Raised2023-07-15
- Q1 FY2022Raised2022-04-15
- Q4 FY2022Raised2022-13-15
- Q3 FY2022Raised2022-10-15
- Q2 FY2022Raised2022-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Imran Nizamudin AlibhaiCEO1 yr 2 mono recorded callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last guidance raise Q2 FY2023
- Avi Daniel ConnCFO1 yr 2 mono recorded callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last call held guidance Q2 FY2023
- John Saewook M.d KauhChief Medical Officer1 yr 2 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2023
- Stephen Paul O'BrienPrincipal Accounting Officer1 yr 2 mono recorded callsCurrentSample
OTHER since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2023
- Jeffrey Leroy LarsonSVP, Research & Development0 mono recorded callsFormerSample
DIVISION_HEAD since 2025 • 1/2 beats (50%) • last call held guidance Q3 FY2023
- Yixin ChenVP, Chem, Mfg and Ctrls0 mono recorded callsFormerSample
OTHER since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2023
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TVRD.
$ curl https://api.spokenalpha.com/v1/companies/TVRDFAQ
Frequently asked about TVRD
Where can I find Tvardi Therapeutics, Inc.'s (TVRD) earnings call transcripts?
Spoken Alpha indexes TVRD's earnings call transcripts at https://spokenalpha.com/companies/TVRD. Each call links to attributed speakers and parsed analyst Q&A. Tvardi Therapeutics, Inc.'s own investor relations page is at https://ir.tvarditherapeutics.com/.
When was Tvardi Therapeutics, Inc.'s most recent earnings call?
Tvardi Therapeutics, Inc. (TVRD) held its most recent earnings call on 2024-03-04, covering fiscal Q4 2023.
What sector is TVRD in?
Tvardi Therapeutics, Inc. (TVRD) operates in the Healthcare sector (Biotechnology industry).